Provided are a method for producing a stereocomplex polylactic acid composite based on oil-in-water emulsion blending, a method for preparing a drug delivery composition using a stereocomplex polylactic acid composite produced by the production method, and a drug delivery composition prepared by the preparation method. The stereocomplex polylactic acid composite is produced using oil-in-water emulsion blending that has the advantages of simple process, short production time, and high stereocomplexation efficiency compared to existing methods such as solution blending, melt-blending, and supercritical fluid technology. In addition, the drug delivery composition is prepared using oil-in-water emulsion blending that allows the drug to be loaded into the polymer chains of the stereocomplex polylactic acid in a very easy and efficient manner and facilitates release of the drug at room temperature over a long period of time.

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals.

The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals.

The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals.

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.